Besides BrBzGSHCp2, troglitazone reduces the Glo1-induced MDR in doxorubicin-resistant K562 leukemia cells, in doxorubicin-resistant MCF7 cells and in astrocytoma cell line U-373 (85–87). This evidence concerns the gene GLO1 and leukemia.